Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B), while Vertex Pharmaceuticals Incorporated trades at $509.67 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 15× Global X NASDAQ 100 Covered Call ETF's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 50 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| QYLD | VRTX | |
|---|---|---|
Market Cap | $8.49B | $127.55B |
Volume | 2,913,938 | 1,487,944 |
Sector | Income / Options Overlay | Health |
52-Week High | $18.68 | $557.96 |
52-Week Low | $16.70 | $407.37 |
Typical Hold Time | 50 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.675, down slightly by 0.03% on the day. The ETF shows a bullish technical signal from moving averages but bearish oscillators, with RSI levels indicating potential overbought conditions. Recent dividend payments of $0.18 per share were distributed monthly, supporting its income-focused strategy. News coverage highlights its high yield but also raises concerns about long-term capital erosion and capped upside.
The outlook for QYLD is mixed; it offers attractive monthly income but faces headwinds from declining option premiums and limited growth potential. Risks include principal erosion and tax implications, making it suitable for income-seeking investors who prioritize cash flow over capital appreciation. Analyst sentiment varies, with some upgrades citing yield attractiveness amid volatility.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
